m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03900)
Name
APO-010
Synonyms
MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget
    Click to Show/Hide
Status
Phase 1
TTD Drug ID
D0Q6SF
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Apoptosis mediating surface antigen FAS (FAS)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APO-010. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of APO-010 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APO-010. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APO-010 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). [2], [3]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APO-010. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of APO-010 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). [2], [4]
References
Ref 1 FTO-dependent function of N6-methyladenosine is involved in the hepatoprotective effects of betaine on adolescent mice. J Physiol Biochem. 2015 Sep;71(3):405-13. doi: 10.1007/s13105-015-0420-1. Epub 2015 Jun 16.
Ref 2 ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Disorders 2010,11:221.
Ref 3 Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012 Apr 29;485(7397):201-6. doi: 10.1038/nature11112.
Ref 4 N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes. Hepatology. 2021 Jan;73(1):91-103. doi: 10.1002/hep.31220. Epub 2020 Oct 25.